RxDoctor Payments DataLook up a doctor →

Vasili Lendel, MD

Interventional Cardiology · Little Rock, ARNPI 1720104516

Payments from drug & device makers

$206,410in general payments, 2019–2025

Across 418 payments — averaging $493.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$78K
  • Cardiovascular Systems Inc.$49K
  • Abbott$36K
  • Shockwave Medical, Inc$24K
  • M.a. Med Alliance S.A.$11K
  • Boston Scientific$1K
  • plus $7K from 26 others

What the payments were for

  • Consulting fees$14,41317%
  • Speaking & faculty fees$56,27065%
  • Travel & lodging$4461%
  • Food & beverage$14,96717%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,410 in reported general payments places this provider in the 95th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$660,495
Medicare patients
2,639
Services billed
9,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban746$702,068
XareltoRivaroxaban770$689,680
EntrestoSacubitril/Valsartan285$288,012
VyndamaxTafamidis12$268,144
FarxigaDapagliflozin Propanediol171$132,828
Repatha SureclickEvolocumab75$62,594
MultaqDronedarone Hcl39$47,196
BrilintaTicagrelor38$29,916
JardianceEmpagliflozin32$22,648
ClopidogrelClopidogrel Bisulfate1,521$15,492
Dofetilide69$11,725
Ranolazine ErRanolazine102$11,294
Metoprolol Succinate885$11,038
Prasugrel Hcl161$10,257
Clonidine60$8,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$129$970,212758 claims
Johnson & JohnsonXarelto$497$689,680770 claims
NovartisEntresto$127$288,012285 claims
AstraZenecaFarxiga, Brilinta$343$162,744209 claims
Sanofi-aventis U.S. LLCMultaq$11$47,19639 claims
Lexicon Pharmaceuticals, Inc.Inpefa$153$6,78911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →